These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

291 related articles for article (PubMed ID: 36643028)

  • 1. Intestinal Barrier Function in the Pathogenesis of Nonalcoholic Fatty Liver Disease.
    Liu L; Yin M; Gao J; Yu C; Lin J; Wu A; Zhu J; Xu C; Liu X
    J Clin Transl Hepatol; 2023 Apr; 11(2):452-458. PubMed ID: 36643028
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Role of Leaky Gut in Nonalcoholic Fatty Liver Disease: A Novel Therapeutic Target.
    Kessoku T; Kobayashi T; Tanaka K; Yamamoto A; Takahashi K; Iwaki M; Ozaki A; Kasai Y; Nogami A; Honda Y; Ogawa Y; Kato S; Imajo K; Higurashi T; Hosono K; Yoneda M; Usuda H; Wada K; Saito S; Nakajima A
    Int J Mol Sci; 2021 Jul; 22(15):. PubMed ID: 34360923
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Role of Gut-Liver Axis in Gut Microbiome Dysbiosis Associated NAFLD and NAFLD-HCC.
    Song Q; Zhang X
    Biomedicines; 2022 Feb; 10(3):. PubMed ID: 35327326
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intestinal permeability in human nonalcoholic fatty liver disease: A systematic review and meta-analysis.
    De Munck TJI; Xu P; Verwijs HJA; Masclee AAM; Jonkers D; Verbeek J; Koek GH
    Liver Int; 2020 Dec; 40(12):2906-2916. PubMed ID: 33037768
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gut dysbiosis in nonalcoholic fatty liver disease: pathogenesis, diagnosis, and therapeutic implications.
    Fang J; Yu CH; Li XJ; Yao JM; Fang ZY; Yoon SH; Yu WY
    Front Cell Infect Microbiol; 2022; 12():997018. PubMed ID: 36425787
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Contribution of gut microbiota to nonalcoholic fatty liver disease: Pathways of mechanisms.
    Bakhshimoghaddam F; Alizadeh M
    Clin Nutr ESPEN; 2021 Aug; 44():61-68. PubMed ID: 34330514
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diammonium Glycyrrhizinate Protects against Nonalcoholic Fatty Liver Disease in Mice through Modulation of Gut Microbiota and Restoration of Intestinal Barrier.
    Li Y; Liu T; Yan C; Xie R; Guo Z; Wang S; Zhang Y; Li Z; Wang B; Cao H
    Mol Pharm; 2018 Sep; 15(9):3860-3870. PubMed ID: 30036479
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gut-liver axis, nutrition, and non-alcoholic fatty liver disease.
    Kirpich IA; Marsano LS; McClain CJ
    Clin Biochem; 2015 Sep; 48(13-14):923-30. PubMed ID: 26151226
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intestinal Barrier and Permeability in Health, Obesity and NAFLD.
    Portincasa P; Bonfrate L; Khalil M; Angelis M; Calabrese FM; D'Amato M; Wang DQ; Di Ciaula A
    Biomedicines; 2021 Dec; 10(1):. PubMed ID: 35052763
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lactobacillus plantarum NA136 ameliorates nonalcoholic fatty liver disease by modulating gut microbiota, improving intestinal barrier integrity, and attenuating inflammation.
    Zhao Z; Chen L; Zhao Y; Wang C; Duan C; Yang G; Niu C; Li S
    Appl Microbiol Biotechnol; 2020 Jun; 104(12):5273-5282. PubMed ID: 32335723
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intestinal microbiota and nonalcoholic steatohepatitis.
    Brandl K; Schnabl B
    Curr Opin Gastroenterol; 2017 May; 33(3):128-133. PubMed ID: 28257306
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of gut microbiota and Toll-like receptors in nonalcoholic fatty liver disease.
    Miura K; Ohnishi H
    World J Gastroenterol; 2014 Jun; 20(23):7381-91. PubMed ID: 24966608
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Probiotics as a complementary therapeutic approach in nonalcoholic fatty liver disease.
    Ferolla SM; Armiliato GN; Couto CA; Ferrari TC
    World J Hepatol; 2015 Mar; 7(3):559-65. PubMed ID: 25848479
    [TBL] [Abstract][Full Text] [Related]  

  • 14. SIRT3 Deficiency Promotes High-Fat Diet-Induced Nonalcoholic Fatty Liver Disease in Correlation with Impaired Intestinal Permeability through Gut Microbial Dysbiosis.
    Chen M; Hui S; Lang H; Zhou M; Zhang Y; Kang C; Zeng X; Zhang Q; Yi L; Mi M
    Mol Nutr Food Res; 2019 Feb; 63(4):e1800612. PubMed ID: 30525304
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mesenteric adipose tissue contributes to intestinal barrier integrity and protects against nonalcoholic fatty liver disease in mice.
    Wu Z; Tan J; Chi Y; Zhang F; Xu J; Song Y; Cong X; Wu N; Liu Y
    Am J Physiol Gastrointest Liver Physiol; 2018 Nov; 315(5):G659-G670. PubMed ID: 29902065
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nonalcoholic Fatty Liver Disease: Basic Pathogenetic Mechanisms in the Progression From NAFLD to NASH.
    Pierantonelli I; Svegliati-Baroni G
    Transplantation; 2019 Jan; 103(1):e1-e13. PubMed ID: 30300287
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Protective effect of quercetin on high-fat diet-induced non-alcoholic fatty liver disease in mice is mediated by modulating intestinal microbiota imbalance and related gut-liver axis activation.
    Porras D; Nistal E; Martínez-Flórez S; Pisonero-Vaquero S; Olcoz JL; Jover R; González-Gallego J; García-Mediavilla MV; Sánchez-Campos S
    Free Radic Biol Med; 2017 Jan; 102():188-202. PubMed ID: 27890642
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of microbiota in nonalcoholic fatty liver disease.
    Di Ciaula A; Bonfrate L; Portincasa P
    Eur J Clin Invest; 2022 Jul; 52(7):e13768. PubMed ID: 35294774
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intestinal microbiota participates in nonalcoholic fatty liver disease progression by affecting intestinal homeostasis.
    Zhang Y; Li JX; Zhang Y; Wang YL
    World J Clin Cases; 2021 Aug; 9(23):6654-6662. PubMed ID: 34447812
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Herbal therapy for ameliorating nonalcoholic fatty liver disease via rebuilding the intestinal microecology.
    Yang XF; Lu M; You L; Gen H; Yuan L; Tian T; Li CY; Xu K; Hou J; Lei M
    Chin Med; 2021 Jul; 16(1):62. PubMed ID: 34315516
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.